Adverse skin reactions induced by BRAF inhibitors: A systematic review;Effets indésirables cutanés des inhibiteurs de BRAF: revue systématique

Annales de Dermatologie et de Venereologie

Volumn 140, Issue 8-9, 2013, Pages 510-520

  Sibaud, V ^a   Lamant, L ^b   Maisongrosse, V ^a   Delord, J P ^c  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CHU PURPAN   (France)

^c Lab de Pharmacocinétique   (France)

Author keywords

BRAF; Dabrafenib; Dermatologic adverse events; Malignant melanoma; Vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; VEMURAFENIB;

ACANTHOLYTIC DYSKERATOSIS; ADVERSE OUTCOME; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; CYST; DARIER DISEASE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GENE MUTATION; HUMAN; INFORMATION RETRIEVAL; KERATINOCYTE; KERATOACANTHOMA; KERATOSIS; MELANOMA; OVERALL SURVIVAL; PHOTOSENSITIVITY; REVIEW; SKIN CYST; SKIN DEFECT; SKIN MANIFESTATION; SKIN PAPILLOMA; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

BRAF; DABRAFENIB; DERMATOLOGIC ADVERSE EVENTS; EFFETS INDÉSIRABLES CUTANÉS; MALIGNANT MELANOMA; MÉLANOME; VEMURAFENIB;

ACANTHOLYSIS; ALOPECIA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CODON; DRUG ERUPTIONS; HAND-FOOT SYNDROME; HUMANS; IMIDAZOLES; INDOLES; KERATOACANTHOMA; KERATOSIS; MELANOMA; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; NEVUS; OXIMES; PANNICULITIS; PHOTOSENSITIVITY DISORDERS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIODERMATITIS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84883894476     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2013.02.031     Document Type: Review

References (43)

1. P.B. Chapman, L.H. Einhorn, M.L. Meyers, S. Saxman, A.N. Destro, and K.S. Panageas Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 1999 2745 2751
2. R.R. Vaillancourt, A.M. Gardner, and G.L. Johnson BRAF-dependent regulation of the MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP Mol Cell Biol 14 1994 6522 6530
3. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
4. A.M. Eggermont, and C. Robert New drugs in melanoma: it's a whole new world Eur J Cancer 47 2011 2150 2157
5. K.T. Flaherty, I. Pueanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
6. J.A. Sosman, K.B. kim, L. Schuster, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Eng J Med 366 2012 707 714
7. G.S. Falschook, G.V. Long, R. Kurzrock, K.B. Kim, T.H. Arkénau, and M.P. Brown Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 2012 1893 1901
8. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
9. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2515
10. K.P. Boyd, B. Vincent, A. Andea, R.M. Conry, and L.C. Hughey Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma J Am Acad Dermatol 67 2012 1375 1379
11. P.L. Mattei, M.B. Alora-Palli, S. Kraft, D.P. Lawrence, K.T. Flaherty, and A.B. Kimball Cutaneous effects of BRAF inhibitor therapy: a case series Ann Oncol 24 2013 530 537 [Epub ahead of print]
12. C. Robert, V. Sibaud, C. Mateus, and B.S. Cherpelis Advances in the management of cutaneous toxicities of targeted therapies Semin Oncol 39 2012 227 240
13. V. Sibaud, I. Garrido-Stowhas, E. Cottura, and C. Chevreau Dermatologic side effects induced by new angiogenesis inhibitors Bull Cancer 98 2011 1221 1229
14. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892
15. D.H. Siegel, J. McKenzie, I.J. Frieden, and K.A. Rauen Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome Br J Dermatol 164 2011 521 529
16. D.H. Siegel, J.A. Mann, A.L. Krol, and K.A. Rauen Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development Br J Dermatol 166 2012 601 607
17. L. Boussemart, C. Mateus, N. Kamsu-Kan, M. Thomas, G. Tomasic, and J. Wechsler Cutaneous side effects associated with the BRAF inhibitor vemurafenib: a prospective study of 42 patients Melanoma Conference, EORTC Paris, (abstract P136) 2012
18. R. Anforth, T.C. Blumetti, R.F. Kéfford, R. Sharma, R.A. Scolyer, and S. Kossard Manifestations of Dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma Br J Dermatol 167 2012 1153 1160
19. R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin, and L. Fearfield Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities Br J Dermatol 167 2012 987 994
20. P.A. Oberholzer, D. Kee, P. Dziunycz, A. Suckér, N. Kamsukom, and R. Jones RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors J Clin Oncol 30 2012 316 321
21. E.Y. Chu, K.A. Wanat, C.J. Miller, R.K. Amaravadi, L.A. Fecher, and M.S. Brose Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study J Am Acad Dermatol 67 2012 1265 1272
22. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, and O. Spleiss RAS mutations in cutaneous squamous cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
23. L. Zimmer, U. Hillen, E. Livingstone, M.E. Lacouture, K. Busam, and R.D. Carvajal Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition J Clin Oncol 30 2012 2375 2383
24. J.P. Arnault, C. Mateus, B. Escudier, G. Tomasic, J. Wechsler, and E. Hollville Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1 Clin Cancer Res 18 2012 263 272
25. R. Anforth, V. Tembe, T.C. Blumetti, and P. Fernandez-Peñas Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking braf inhibitors Pigment Cell Melanoma Res 25 2012 569 572
26. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem Improved survival with MEK inhibition in BRAF-mutated melanoma N Eng J Med 367 2012 107 114
27. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kéfford, and J. Sosman Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
28. R. Anforth, T.C. Blumetti, A. Mohd Affandi, and P. Fernandez-Penas Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib J Clin Oncol 30 2012 e165 e167
29. A. Alloo, L. Garibyan, N. Leboeuf, G. Lin, A. Werchniak, and F.S. Hodi Photodynamic therapy for multiple eruptive keratoacantomas associatecd with vemurafenib treatment for metastatic melanoma Arch Dermatol 148 2012 363 366
30. V. Huang, D. Hepper, M. Anadkat, and L. Cornelius Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway Arch Dermatol 148 2012 628 633
31. C.M. Wang, K.F. Fleming, and S. Hsu A case of vemurafenib-induced keratosis pilaris-like eruption Dermatol Online J 18 2012 7
32. J.J. Harding, M. Pulitzer, and P.B. Chapman Vemurafenib sensitivity skin reaction after ipilimumab N Engl J Med 366 2012 866 868
33. M. Gupta, V. Huang, G. Linette, and L. Cornelius Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by kaposi varicelliform eruption Arch Dermatol 148 2012 966 968
34. M.W. Saif Capecitabine and hand-foot syndrome Expert Opin Drug Saf 10 2011 159 169
35. M.E. Lacouture, S. Wu, C. Robert, M.B. Atkins, H.H. Kong, and J. Guitart Evolving strategies for the management of hand-foot syndrome skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 2008 1001 1011
36. R. Dummer, J. Rinderknecht, and S.M. Goldinger Ultraviolet A and photosensitivity during vemurafenib therapy N Eng J Med 366 2012 480 481
37. V. Sibaud, J.C. Fricain, R. Baran, and C. Robert Troubles pigmentaires induits pas les agents anticancéreux. Première partie: chimiothérapies Ann Dermatol Venereol 140 2013 183 196
38. H.H. Kong, V. Sibaud, M.L. Chanco Turner, T. Fojo, T.J. Hornyak, and C. Chevreau Sorafenib-induced eruptive melanocytic lesions Arch Dermatol 144 2008 820 822
39. H.A. Haenssle, S.L. Kraus, F. Brehmer, L. Kretschmer, B. Völker, and H. Asper Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy Arch Dermatol 20 2012 1 3
40. S. Dalle, N. Poulalhon, and L. Thomas Vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 13 2011 1448 1449
41. L. Zimmer, E. Livingstone, U. Hillen, S. Domkes, A. Becker, and D. Schadendorf Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management Arch Dermatol 148 2012 357 361
42. V. Sibaud, and C. Chevreau Dermatologic manifestations of angiogenesis inhibitors V. Sibaud, C. Robert, Cutaneous side effects induced by targeted anticancer therapies: a new dermatology 2010 Privat Toulouse 41 59
43. L. Boussemard, C. Boivin, J. Claveau, Y.G. Tao, G. Tomasic, and E. Routier Vemurafenib and radiosensitization Arch Dermatol 2013 10.1001/jamadermatol.2013.4200 [In press]